Search the Newsreel

CrossAmerica Partners LP's Dividend Analysis

Versamet Royalties Corp. Revenue Breakdown – TSX:VMET

Versamet Royalties Corp. (TSX: VMET) reported a total revenue of 47.74 million CAD last year. The Gold segment was the highest performing, generating 33.51 million CAD, an increase from 13.68 million CAD in the previous year. Canada was the primary regional contributor, accounting for …

gossamer bio inc. Earnings dates

This article provides the upcoming earnings dates for Gossamer Bio Inc. (GOSS), including estimates for Q3 2024 and Q4 2025. It also lists recent news headlines related to Gossamer Bio, covering topics such as FDA filings, clinical trial results, and acquisitions.

BlackRock (GOSS) discloses 4.89M-share, 1% beneficial stake in Gossamer Bio

BlackRock, Inc. has filed an amended ownership report disclosing a beneficial stake of 4,890,593 shares, representing 1.0% of Gossamer Bio, Inc.'s common stock, as of June 30, 2026. BlackRock holds sole voting and sole dispositive power over these shares. This filing, a Schedule 13G/A, …

Gossamer Bio Inc (GOSS) Institutional Confidence

Gossamer Bio Inc (GOSS) has an institutional shareholding score of 7.00, placing it 80th out of 385 in its industry. The latest institutional shareholding proportion is 73.39%, representing a quarterly decrease of 6.63%. James Simons is identified as the largest institutional shareholder, holding 0.52% …

CrossAmerica Partners (CAPL) Expected to Post Earnings on Wednesday

Understanding Momentum Shifts in (CAPL)

This article analyzes momentum shifts for Crossamerica Partners Lp (CAPL) using AI models, offering institutional-grade trading strategies for different risk profiles. It highlights a neutral near and mid-term outlook that could moderate a long-term positive bias, alongside specific entry, target, and stop-loss levels for …

Opaleye group (NASDAQ: GOSS) reports 24.9M-share, 5.10% Gossamer Bio position

Opaleye Management Inc., along with Opaleye, L.P., and James Silverman, has disclosed a 5.10% beneficial ownership stake in Gossamer Bio, Inc. (GOSS), totaling 24,942,565 shares. This includes 24,141,629 shares held directly by Opaleye, L.P. and an additional 800,936 shares in a separately managed account. …

Update: Gossamer Bio Extends Gains Pre-Bell Following New Drug Application Filing Plans for Pulmonary Arterial Hypertension Treatment

Gossamer Bio's stock showed significant pre-bell gains after the company announced its plans to file a New Drug Application (NDA) for its pulmonary arterial hypertension (PAH) treatment, seralutinib. This positive market response follows encouraging trial results for the drug. The company expects to submit …

Leerink upgrades Gossamer Bio stock rating on FDA feedback

Leerink upgraded Gossamer Bio Inc. (NASDAQ:GOSS) to Outperform from Market Perform, raising its price target to $1.00 following positive FDA feedback on the company's PROSERA trial. The FDA's assessment of the trial's statistical significance as a review issue rather than a filing issue reduced …

Gossamer Bio (GOSS) Projected to Release Quarterly Earnings on Tuesday

Leerink Partners Upgrades Gossamer Bio(GOSS.US) to Buy Rating, Cuts Target Price to $1

Leerink Partners has upgraded its rating for Gossamer Bio (GOSS.US) to "Buy." Despite the upgrade, the target price for the stock has been reduced to $1.

Gossamer Bio Inc (GOSS) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of Gossamer Bio Inc (GOSS), detailing its current price momentum, support and resistance levels, and various technical indicators and moving averages. The stock currently has a price momentum score of 6.30 and is trading within a range suitable …

12 Health Care Stocks Moving In Monday's After-Market Session

This article lists 12 healthcare stocks that experienced significant movement in Monday's after-market session, highlighting both gainers and losers. Notable gainers include Gossamer Bio, ProMIS Neurosciences, OPKO Health, OrthoPediatrics, Matinas BioPharma Hldgs, and Olema Pharmaceuticals. Conversely, Radiopharm Theranostics, Redhill Biopharma, HeartSciences, iBio, Cumberland Pharma, …

Gossamer Reacquires Global Seralutinib Rights From Chiesi, Receives $5 Million

Gossamer Bio has reacquired the global development and commercial rights for seralutinib from Chiesi, terminating their 2024 Collaboration and License Agreement. Chiesi will pay Gossamer $5 million for development costs, while Gossamer will pay success-based milestones and royalties to Chiesi. This move returns key …

Gossamer Bio shares jump after FDA update and seralutinib rights return

Gossamer Bio (NASDAQ:GOSS) shares surged 25% following a positive FDA regulatory update for its lead drug candidate, seralutinib, and the regaining of full global rights to the therapy. The company anticipates submitting a New Drug Application (NDA) for seralutinib in pulmonary arterial hypertension (PAH) …

Gossamer Bio stock surges 25% on FDA regulatory update

Gossamer Bio Inc. (NASDAQ:GOSS) shares surged 25% after the company announced a regulatory update from the FDA regarding its drug seralutinib for pulmonary arterial hypertension (PAH) and reacquired worldwide rights to the drug. The company plans to submit a New Drug Application (NDA) for …

Gossamer Bio shares surge after FDA filing update; cash concerns and dilution still loom

Versamet Royalties Ord Shs (VMET) Financial Health: Profitability & Balance Sheet Analysis

Gossamer Bio, Inc. Revenue Breakdown – SWB:4GB

This article from TradingView provides a high-level overview of Gossamer Bio, Inc.'s financial information on the Stuttgart Stock Exchange (SWB:4GB). It indicates that the primary financial segment information for revenue breakdown, including source and country, is not publicly available on this specific page. The …

GOSS|Gossamer Bio Inc|Price:0.136|Chg%:-0.006

Gossamer Bio Inc. (GOSS) is a late-stage biopharmaceutical company focusing on seralutinib for pulmonary arterial hypertension. The company exhibits stable fundamentals and high growth potential but is currently considered fairly valued within its industry. Despite weak recent stock market performance, its stock price is …

Form 13D/A Gossamer Bio For: 24 July By Investing.com

This article announces the filing of a Form 13D/A for Gossamer Bio on July 24. The filing is a standard regulatory disclosure related to significant ownership stakes in a company. The article itself is very brief, mainly serving as an announcement for this regulatory …

CrossAmerica Partners (NYSE: CAPL) director gains 3,154 common units

CrossAmerica Partners LP director Kenneth G. Valosky gained 3,154 common units after exercising vested phantom units on July 23, 2026. Following this conversion, he directly holds 26,958 common units. The phantom units were economically equivalent to common units and contributed to his total holdings.

CrossAmerica Partners names CFO

This story was originally published on C-Store Dive. To receive daily news and insights, subscribe to our free daily C-Store Dive newsletter. CrossAmerica Partners has named Jonathan Benfield as its chief financial officer, according to a filing with the U.S. Securities and Exchange Commission …

Gossamer Bio Inc (GOSS) Valuation: PE, PB & Fair Value Analysis

This article provides a valuation analysis of Gossamer Bio Inc (GOSS), noting its current valuation score of 7.94 within the Biotechnology & Medical Research industry. It highlights the company's P/E ratio and mentions that relevant data for P/B, P/S, and P/CF ratios have not …

D. E. Shaw group reports 7.1% stake in Gossamer Bio (GOSS)

The D. E. Shaw group has updated its ownership disclosure for Gossamer Bio (GOSS), revealing affiliated investment entities collectively hold a 7.1% stake, totaling 34,609,565 common shares. This ownership is distributed among D. E. Shaw Valence Portfolios (6.7%), D. E. Shaw Cogence Portfolios (0.3%), …

Category managers from Weigel’s, CrossAmerica Partners, Southwest Georgia Oil and R.L. Jordan Oil share tobacco trends and challenges

This article compiles insights from category managers at Weigel’s, CrossAmerica Partners, Southwest Georgia Oil, and R.L. Jordan Oil regarding the evolving tobacco market. They discuss the challenges and trends in their roles, highlighting the rapid pace of change, the growth of modern oral nicotine, …

CrossAmerica Partners declares $0.525 dividend

* CrossAmerica Partners (CAPL [https://seekingalpha.com/symbol/CAPL]) declares $0.525/share quarterly dividend [https://seekingalpha.com/pr/20590528-crossamerica-partners-lp-maintains-quarterly-distribution], in line with previous. * Forward yield [https://seekingalpha.com/symbol/CAPL/dividends/yield?source=news_bullet] 9.43% * Payable Aug. 13; for shareholders of record Aug. 3; ex-div Aug. 3. * See CAPL Dividend Scorecard, Yield Chart, & Dividend Growth. [https://seekingalpha.com/symbol/CAPL/dividends?source=news_bullet] MORE …

Crossamerica Partners LP (CAPL) Q2 2023 Earnings Report - Results, Call & Slides

Crossamerica Partners LP (CAPL) released its Q2 2023 earnings report, announcing an actual EPS of $0.36, beating the consensus estimate of $0.15. However, the company missed revenue expectations, reporting $1.15 billion against an expected $1.20 billion, marking a 22.35% year-over-year revenue decline. The earnings …

CrossAmerica Partners LP Maintains $0.525 Quarterly Distribution for Q2 2026 and Announces Earnings Call

CrossAmerica Partners LP (NYSE: CAPL) announced it will maintain its quarterly distribution of $0.5250 per unit for the second quarter of 2026, payable on August 13, 2026, to unitholders of record as of August 3, 2026. The company will also host an earnings call …

Form 4 Crossamerica Partners LP For: 21 July By Investing.com

This article announces the filing of Form 4 for Crossamerica Partners LP on July 21. It indicates that the document is available for review, likely pertaining to insider trading activities or changes in ownership. The content itself is very brief and mostly consists of …

CrossAmerica sets Aug. 13 payment for $0.525 per unit

CrossAmerica Partners LP (NYSE: CAPL) has announced a quarterly distribution of $0.5250 per unit for the second quarter of 2026, which annualizes to $2.10 per unit. This distribution will be paid on August 13, 2026, to unitholders of record as of August 3, 2026. …

CrossAmerica Partners (NYSE: CAPL) awards 3,040 phantom units to director Reilly

CrossAmerica Partners LP director and 10% owner John B. Reilly III was granted 3,040 phantom units as equity compensation on July 21, 2026, increasing his total holdings to 36,507 phantom units. These units are economically equivalent to common units and include distribution equivalent rights. …

Gossamer Bio stock edges higher as trial setbacks and restructuring reshape outlook

Gossamer Bio's stock reflects a mixed sentiment as the biotechnology company embarks on a restructuring phase following the discontinuation of its lead GB002 program. The company reported a significant reduction in net loss for 2023 due to decreased operating expenses and a refocused R&D …

CrossAmerica Partners LP (CAPL) Q1 2026 Earnings: Stellar EPS Surprise Drives Modest Stock Reaction - SaaS Earnings Trends

CrossAmerica Partners LP (CAPL) Q1 2026 Earnings: Stellar EPS Surprise Drives Modest Stock Reaction - Earnings Season Review